Lexaria Bioscience (LEXX) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Lexaria Bioscience (LEXX) over the last 14 years, with Q4 2025 value amounting to 0.81.
- Lexaria Bioscience's Equity Ratio fell 1535.12% to 0.81 in Q4 2025 from the same period last year, while for Nov 2025 it was 0.81, marking a year-over-year decrease of 1535.12%. This contributed to the annual value of 0.72 for FY2025, which is 1709.16% down from last year.
- As of Q4 2025, Lexaria Bioscience's Equity Ratio stood at 0.81, which was down 1535.12% from 0.72 recorded in Q3 2025.
- In the past 5 years, Lexaria Bioscience's Equity Ratio ranged from a high of 1.54 in Q1 2023 and a low of 0.72 during Q3 2025
- Over the past 5 years, Lexaria Bioscience's median Equity Ratio value was 0.97 (recorded in 2022), while the average stood at 0.98.
- In the last 5 years, Lexaria Bioscience's Equity Ratio skyrocketed by 5685.03% in 2023 and then tumbled by 3001.9% in 2024.
- Lexaria Bioscience's Equity Ratio (Quarter) stood at 0.98 in 2021, then increased by 8.17% to 1.06 in 2022, then increased by 2.37% to 1.08 in 2023, then decreased by 11.29% to 0.96 in 2024, then dropped by 15.35% to 0.81 in 2025.
- Its Equity Ratio stands at 0.81 for Q4 2025, versus 0.72 for Q3 2025 and 0.82 for Q2 2025.